权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Therapeutic Lymphatic Vessel Regeneration

淋巴管再生治疗

基本信息

批准号：
9022162
负责人：
Feng Zhao
金额：
$ 46.5万
依托单位：
MICHIGAN TECHNOLOGICAL UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9022162
关键词：
Academic Research Enhancement Awards Anti-Inflammatory Agents Anti-inflammatory Autologous Axilla Axillary Lymph Node Dissection Biological Biomaterials Research Cell Adhesion Cells Chronic Cicatrix Coculture Techniques Dependence Disease Drainage procedure Edema Effectiveness Engineering Environment Extracellular Matrix Extracellular Matrix Proteins Fibrosis Forearm Generations Goals Growth In Vitro Injection of therapeutic agent Injury Intramuscular Life Lymph Lymph Node Dissections Lymphangiogenesis Lymphatic Lymphatic Capillaries Lymphatic Endothelial Cells Lymphatic vessel Lymphedema Lymphoid Tissue Mediating Mentorship Mesenchymal Stem Cells Michigan Modeling Natural regeneration Obstruction Oxygen Physiological Play Production Property Quality of life Rattus Records Research Research Assistant Risk Role Site Staging Stem cells Swelling Technology Therapeutic Tissue Engineering Tissues Training Training Support Transplanted tissue Vascular Endothelial Growth Factor C Vascular Endothelial Growth Factor D Vascular Endothelial Growth Factors Woman Wound Healing arm base cell motility cellular engineering cytokine effective therapy experience implantation improved in vivo in vivo regeneration injured interstitial lymph flow malignant breast neoplasm nanofiber public health relevance regenerative restoration scaffold self-renewal stem cell therapy stemness tissue regeneration undergraduate research undergraduate student

项目摘要

DESCRIPTION (provided by applicant): Secondary lymphedema is a lifelong and occasionally life-threatening disease that often occurs as a consequence of axillary clearance for breast cancer. Regeneration of lymphatic tissues and restoration of lymph flow through a fibrotic scar are two basic essentials for the treatment of secondary lymphedema. Mesenchymal stem cells (MSCs) hold great therapeutic potential due to their effectiveness in stimulating host tissue regeneration via secreting numerous pro-regenerative factors dependent on the specific demands of the type and stage of injury. However, MSCs tend to differentiate and lose their self-renewal ability during the ex vivo expansion. Also, direct delivery of MSCs through injection will lose the function of extracellular matrix (ECM) proteins, which also play an important role in the lymphatic tissue regeneration and which tend to be absent in fibrotic tissues. We propose to use MSCs to fabricate both MSC cell sheet fragments as well as a completely biological tissue-engineered lymphtic collecting vessel (TELCV) under physiologically low oxygen tension, which can effectively promote the ECM production, and maintain the stemness of MSCs and thus their regenerative factor secreting capacity and differentiation ability. Our central hypothesis is that the local administration of MSC fragments, combined with a MSC-based TELCV, will significantly reduce lymphatic edema and improve lymphatic regeneration via the in-site formation of functional lymphatic vasculature and the restoration of lymphatic drainage. The proposed study applies advanced stem cell engineering technology in lymphedema treatment. Upon completion, it will provide an effective treatment of secondary lymphedema, and thereby hold great potential in significantly improving the life quality of women suffering from lymphedema. This Academic Research Enhancement Award (AREA) will also allow us to train undergraduate students with hands-on experience in stem cell and tissue engineering research.